Seer (NASDAQ:SEER) Raised to "Strong-Buy" at Canaccord Genuity Group

Key Points

• Canaccord upgraded Seer to a "Strong-Buy" and TD Cowen also moved to Strong Buy; the consensus rating is "Buy" with an average target price of $4.00.
• SEER is trading down (~4.6%) around $1.86 with a market cap of about $105 million, a 12‑month range of $1.65–$2.41, and a negative PE of -1.45.
• In the latest quarter Seer reported EPS of ($0.29) — beating estimates by $0.03 — with $4.2M revenue (below estimates) and a very large negative net margin (~-443.96%) and negative ROE.

Seer (NASDAQ:SEER - Get Free Report) was upgraded by Canaccord Genuity Group to a "strong-buy" rating in a report released on Monday,Zacks.com reports.

A number of other equities analysts have also weighed in on SEER. TD Cowen upgraded shares of Seer to a "strong-buy" rating in a research report on Monday, April 13th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Seer in a report on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $4.00.

Seer Trading Down 4.6%

NASDAQ SEER opened at $1.86 on Monday. Seer has a 12 month low of $1.65 and a 12 month high of $2.41. The stock has a market cap of $104.94 million, a PE ratio of -1.45 and a beta of 1.63. The stock's 50 day moving average is $1.83 and its 200 day moving average is $1.91.

Seer (NASDAQ:SEER - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.03. The business had revenue of $4.20 million during the quarter, compared to analyst estimates of $4.60 million. Seer had a negative net margin of 443.96% and a negative return on equity of 26.04%.

Institutional Investors Weigh In On Seer

Several large investors have recently bought and sold shares of SEER. Squarepoint Ops LLC raised its stake in Seer by 57.0% during the third quarter. Squarepoint Ops LLC now owns 91,906 shares of the company's stock valued at $199,000 after purchasing an additional 33,349 shares in the last quarter. XTX Topco Ltd bought a new position in Seer during the second quarter valued at $172,000. Shay Capital LLC grew its stake in shares of Seer by 17.7% in the 3rd quarter. Shay Capital LLC now owns 73,571 shares of the company's stock worth $160,000 after buying an additional 11,073 shares in the last quarter. Corient Private Wealth LLC grew its stake in shares of Seer by 46.3% in the 2nd quarter. Corient Private Wealth LLC now owns 63,200 shares of the company's stock worth $135,000 after buying an additional 20,000 shares in the last quarter. Finally, Barclays PLC increased its holdings in shares of Seer by 685.0% in the 4th quarter. Barclays PLC now owns 60,717 shares of the company's stock worth $111,000 after buying an additional 52,982 shares during the last quarter. Institutional investors own 75.20% of the company's stock.

Seer Company Profile

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer's platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company's flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.